Shardul Amarchand Mangaldas & Co (SAM) advised Evonile Pharma Limited, on its acquisition of the ‘Minipress’ and ‘Minipres’ brands in India from Pfizer for an aggregate consideration of approximately ₹1,250 crores. The transaction signed and closed on September 7, 2026. SAM advised Evonile Pharma Limited on all aspects of the transaction. The transaction was led … Continue reading SAM advises Evonile Pharma Limited on acquisition of ‘Minipress’ and ‘Minipres’ brands from Pfizer